James B. Yu, MD

Articles

Dr Yu discusses the ARCAD Nomogram in a Real-World CRC Population

February 2nd 2024

James Yu, MD, discusses the validation of the ARCAD nomogram in the real-world setting for patients with stage IV colorectal cancer.

Dr. Yu on the Role of Radiation in Prostate Cancer

November 6th 2020

James B. Yu, MD, MHS, discusses the utility of radiation in men with prostate cancer.

Dr. Yu on the Drawbacks of Radiation Therapy in Prostate Cancer

June 6th 2019

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses drawbacks of radiation therapy in prostate cancer.

Dr. Yu on the Importance of a Genetic Counselor in Prostate Cancer

April 14th 2018

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses the importance of a genetic counselor in the treatment of patients with prostate cancer.

Dr. Yu on Emerging Standards in Radiation for Prostate Cancer

April 2nd 2018

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses emerging standards in radiation for the treatment of patients with prostate cancer.

Dr. Yu Compares Treatment Options for Prostate Cancer

August 4th 2017

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses radiotherapy versus surgery for patients with prostate cancer.

Dr. Yu on the Significance of the PROTECT Study in Prostate Cancer

May 9th 2017

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses the significance of the PROTECT study results in prostate cancer.

Dr. Yu on Moderate Hypofractionation in Prostate Cancer

May 2nd 2017

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses moderate hypofractionation replacing the current standard of care for patients with prostate cancer.

Dr. Yu on Trials of Moderate Hypofractionation in Prostate Cancer

April 12th 2017

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses current data in support of using moderate hypofractionation in prostate cancer.

Changes in Prostate Cancer Presentation for Radiation Oncology Care

October 3rd 2015

USPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.